Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 4:04 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 543349 | NSE: ACUTAAS

Acutaas Chemicals Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹1,473.46Overvalued by 36.82%vs CMP ₹2,332.00

P/E (66.5) × ROE (16.0%) × BV (₹173.00) × DY (0.06%)

₹715.98Overvalued by 69.30%vs CMP ₹2,332.00
MoS: -225.7% (Negative)Confidence: 68/100 (Moderate)Models: All 9: Overvalued
ModelCategoryValueWeightSignal
PE-ROEEarnings₹1,898.5123%Over (-18.6%)
Graham NumberEarnings₹369.3717%Over (-84.2%)
Earnings PowerEarnings₹90.8011%Over (-96.1%)
DCFCash Flow₹853.0511%Over (-63.4%)
Net Asset ValueAssets₹172.707%Over (-92.6%)
EV/EBITDAEnterprise₹315.369%Over (-86.5%)
Earnings YieldEarnings₹350.507%Over (-85%)
ROCE CapitalReturns₹452.739%Over (-80.6%)
Revenue MultipleRevenue₹122.996%Over (-94.7%)
Consensus (9 models)₹715.98100%Overvalued
Key Drivers: EPS CAGR 28.8% lifts DCF — verify sustainability. | Wide model spread (₹91–₹1,899) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 28.8%

*Investments are subject to market risks

Investment Snapshot

70
Acutaas Chemicals Ltd scores 70/100 (Strong)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health72/100 · Strong
ROCE 19.9% GoodROE 16.0% GoodD/E 0.70 ModerateInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money75/100 · Strong
FII holding up 0.19% (6mo) Slight increaseDII holding up 3.39% MF buyingPromoter holding at 32.7% Stable
Earnings Quality40/100 · Moderate
OPM stable around 21% SteadyWorking capital: 123 days Capital intensive
Quarterly Momentum100/100 · Strong
Revenue (4Q): +31% YoY AcceleratingProfit (4Q): +130% YoY StrongOPM: 38.0% (up 13.0% YoY) Margin expansion
Industry Rank75/100 · Strong
P/E 66.5 vs industry 53.8 In-lineROCE 19.9% vs industry 16.4% Above peers3Y sales CAGR: 25% High growth

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 4:04 am

Market Cap 19,093 Cr.
Current Price 2,332
Intrinsic Value₹715.98
High / Low 2,688/930
Stock P/E66.5
Book Value 173
Dividend Yield0.06 %
ROCE19.9 %
ROE16.0 %
Face Value 5.00
PEG Ratio2.31

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Acutaas Chemicals Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Acutaas Chemicals Ltd 19,093 Cr. 2,332 2,688/93066.5 1730.06 %19.9 %16.0 % 5.00
Astrazeneca Pharma India Ltd 19,630 Cr. 7,852 10,691/6,50294.4 3200.41 %33.4 %23.6 % 2.00
ERIS Lifesciences Ltd 18,152 Cr. 1,310 1,910/1,09740.9 2270.56 %12.2 %12.9 % 1.00
Natco Pharma Ltd 17,945 Cr. 1,002 1,060/66011.5 4830.60 %32.8 %28.0 % 2.00
Wockhardt Ltd 20,598 Cr. 1,268 1,870/1,087190 2810.00 %3.75 %1.22 % 5.00
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Acutaas Chemicals Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 152186154172166225177247275308207306393
Expenses 122146120148140182147198206224156211243
Operating Profit 314134252743304969855195151
OPM % 20%22%22%14%16%19%17%20%25%28%25%31%38%
Other Income 3-01-3031182616105
Interest 1111324011111
Depreciation 33444567678810
Profit before tax 303731-102437205063835896145
Tax % 25%26%28%71%25%31%26%25%28%24%24%25%27%
Net Profit 222722-171826153845634472106
EPS in Rs 3.063.732.71-2.552.273.411.714.565.497.635.418.8213.19

Last Updated: February 3, 2026, 6:46 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 26, 2026, 7:16 pm

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 1601882392403415206177171,0071,215
Expenses 137157196198260415493589775833
Operating Profit 2331424280105123128232382
OPM % 14%16%18%17%24%20%20%18%23%31%
Other Income 0302134-251736
Interest 3356662663
Depreciation 123441012162734
Profit before tax 19283535729111282216382
Tax % 35%35%34%21%25%21%26%41%26%
Net Profit 1218232754728349160285
EPS in Rs 40.1761.6711.1013.088.579.8711.435.8019.3835.05
Dividend Payout % 0%0%0%0%0%15%13%26%8%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)50.00%27.78%17.39%100.00%33.33%15.28%-40.96%226.53%
Change in YoY Net Profit Growth (%)0.00%-22.22%-10.39%82.61%-66.67%-18.06%-56.24%267.49%

Acutaas Chemicals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2017-2018 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:%
5 Years:33%
3 Years:25%
TTM:40%
Compounded Profit Growth
10 Years:%
5 Years:41%
3 Years:30%
TTM:205%
Stock Price CAGR
10 Years:%
5 Years:%
3 Years:39%
1 Year:97%
Return on Equity
10 Years:%
5 Years:16%
3 Years:14%
Last Year:16%

Last Updated: September 5, 2025, 2:16 pm

Balance Sheet

Last Updated: December 4, 2025, 2:21 am

MonthMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 221010323636374141
Reserves 3756721011354865586371,2691,373
Borrowings 2744545913714217138
Other Liabilities 43547761110136169205227274
Total Liabilities 1091552132324136597671,0961,5491,696
Fixed Assets 28327985186205259427570700
CWIP 11302120330125130152
Investments 1322122000
Other Assets 6891131133225450477543848843
Total Assets 1091552132324136597671,0961,5491,696

Reserves and Borrowings Chart

Cash Flow

MonthMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 298152728-1266125118
Cash from Investing Activity + -19-25-21-24-101-121-33-365-224
Cash from Financing Activity + -7156072140-12239261
Net Cash Flow 3-2-03-1820-1156
Free Cash Flow 10-16-76-77-46-31-190-76
CFO/OP 153%53%68%85%52%10%73%116%71%

Free Cash Flow

MonthMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-4.00-13.00-12.00-17.00-57.00104.00119.00-89.00219.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 839711686129115136105105
Inventory Days 768995148123150131139119
Days Payable 148154168146172158157119103
Cash Conversion Cycle 1131438880107111125121
Working Capital Days 466428345114113979123
ROCE %38%34%27%33%24%21%16%20%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 39.41%39.41%38.93%39.91%39.91%35.98%35.97%35.96%35.96%32.66%32.66%32.66%
FIIs 6.36%6.73%7.15%11.66%8.98%12.93%13.87%15.52%16.48%16.94%16.84%16.67%
DIIs 3.63%5.12%5.95%7.58%6.80%14.81%19.93%20.23%18.31%22.38%22.59%21.70%
Government 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.01%0.01%0.01%0.01%0.01%
Public 50.62%48.74%47.97%40.85%44.31%36.28%30.24%28.27%29.22%28.00%27.89%28.96%
No. of Shareholders 78,78670,35272,89783,34495,78490,98793,39495,7561,14,0601,19,8901,08,6641,10,363

Shareholding Pattern Chart

No. of Shareholders

Acutaas Chemicals Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Kotak Multicap Fund 1,466,139 1.33 316.511,366,1392026-03-23 01:07:547.32%
SBI Healthcare Opportunities Fund 900,000 4.77 194.291,000,0002025-11-02 14:30:42-10%
SBI Large & Midcap Fund 900,000 0.5 194.291,100,0002026-03-23 01:28:44-18.18%
UTI Small Cap Fund 524,144 2.49 113.15592,9832025-11-02 14:30:42-11.61%
Kotak Balanced Advantage Fund 450,016 0.55 97.15390,0002026-01-25 01:11:1815.39%
ITI Small Cap Fund 439,743 3.5 94.93440,0652026-02-23 00:40:58-0.07%
Union Small Cap Fund 360,154 4.35 77.75350,1542025-11-02 14:30:422.86%
Motilal Oswal Focused Fund 334,204 4.96 72.15N/AN/AN/A
Mahindra Manulife Small Cap Fund 242,221 1.28 52.29N/AN/AN/A
Bank of India Small Cap Fund 227,000 2.57 49353,0002026-01-25 01:11:18-35.69%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 19.8111.6722.8621.0317.14
Diluted EPS (Rs.) 19.8111.6622.8621.0317.14
Cash EPS (Rs.) 45.6917.5626.2522.5118.47
Book Value[Excl.RevalReserv]/Share (Rs.) 319.93185.13163.01143.3452.99
Book Value[Incl.RevalReserv]/Share (Rs.) 319.93185.13163.01143.3452.99
Revenue From Operations / Share (Rs.) 245.97194.54169.26142.75108.13
PBDIT / Share (Rs.) 60.8336.8734.8329.6225.88
PBIT / Share (Rs.) 54.3332.5231.4526.8624.55
PBT / Share (Rs.) 52.8122.2130.7925.1022.77
Net Profit / Share (Rs.) 39.1913.2122.8619.7517.14
NP After MI And SOA / Share (Rs.) 38.7711.6022.8619.7517.14
PBDIT Margin (%) 24.7318.9520.5820.7523.93
PBIT Margin (%) 22.0816.7118.5718.8122.70
PBT Margin (%) 21.4611.4118.1817.5821.05
Net Profit Margin (%) 15.936.7813.5013.8315.85
NP After MI And SOA Margin (%) 15.765.9613.5013.8315.85
Return on Networth / Equity (%) 12.116.3414.0213.7732.34
Return on Capital Employeed (%) 16.5014.7918.9618.4731.28
Return On Assets (%) 10.243.9010.8610.9113.06
Long Term Debt / Equity (X) 0.000.160.000.000.43
Total Debt / Equity (X) 0.010.320.010.000.70
Asset Turnover Ratio (%) 0.760.770.860.971.06
Current Ratio (X) 3.911.742.893.321.30
Quick Ratio (X) 3.021.192.152.450.93
Inventory Turnover Ratio (X) 5.983.192.993.273.10
Dividend Payout Ratio (NP) (%) 7.7325.5513.120.000.00
Dividend Payout Ratio (CP) (%) 6.6218.5811.430.000.00
Earning Retention Ratio (%) 92.2774.4586.880.000.00
Cash Earning Retention Ratio (%) 93.3881.4288.570.000.00
Interest Coverage Ratio (X) 40.0422.8952.6216.8514.51
Interest Coverage Ratio (Post Tax) (X) 26.8014.6035.5312.2310.61
Enterprise Value (Cr.) 9764.074208.123184.013543.730.00
EV / Net Operating Revenue (X) 9.705.875.166.810.00
EV / EBITDA (X) 39.2130.9525.0932.830.00
MarketCap / Net Operating Revenue (X) 9.935.635.257.000.00
Retention Ratios (%) 92.2674.4486.870.000.00
Price / BV (X) 7.635.995.456.970.00
Price / Net Operating Revenue (X) 9.935.635.257.000.00
EarningsYield 0.010.010.020.010.00

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Acutaas Chemicals Ltd. is a Public Limited Listed company incorporated on 12/06/2007 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L24100GJ2007PLC051093 and registration number is 051093. Currently Company is involved in the business activities of Manufacture of organic and inorganic chemical compounds. Company's Total Operating Revenue is Rs. 989.83 Cr. and Equity Capital is Rs. 40.93 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsPlot No. 440/4, 5 & 6, Surat Gujarat 394230Contact not found
Management
NamePosition Held
Mr. Nareshkumar Ramjibhai PatelExe.Chairman & Mng.Director
Mr. Virendra Nath MishraWhole Time Director
Mr. Ram Mohan Rao LocandeWhole Time Director
Mr. Chetankumar Chhaganlal VaghasiaWhole Time Director
Mr. Hetal Madhukant GandhiIndependent Director
Mr. Girikrishna Suryakant ManiarIndependent Director
Mrs. Richa Manoj GoyalIndependent Director
Dr. Anita BandyopadhyayIndependent Director

FAQ

What is the intrinsic value of Acutaas Chemicals Ltd and is it undervalued?

As of 12 April 2026, Acutaas Chemicals Ltd's intrinsic value is ₹715.98, which is 69.30% lower than the current market price of ₹2,332.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (16.0 %), book value (₹173), dividend yield (0.06 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Acutaas Chemicals Ltd?

Acutaas Chemicals Ltd is trading at ₹2,332.00 as of 12 April 2026, with a FY2026-2027 high of ₹2,688 and low of ₹930. The stock is currently near its 52-week high. Market cap stands at ₹19,093 Cr..

How does Acutaas Chemicals Ltd's P/E ratio compare to its industry?

Acutaas Chemicals Ltd has a P/E ratio of 66.5, which is above the industry average of 53.84. The premium over industry average may reflect growth expectations or speculative interest.

Is Acutaas Chemicals Ltd financially healthy?

Key indicators for Acutaas Chemicals Ltd: ROCE of 19.9 % indicates efficient capital utilization; ROE of 16.0 % shows strong shareholder returns. Dividend yield is 0.06 %.

Is Acutaas Chemicals Ltd profitable and how is the profit trend?

Acutaas Chemicals Ltd reported a net profit of ₹160 Cr in Mar 2025 on revenue of ₹1,007 Cr. Compared to ₹72 Cr in Mar 2022, the net profit shows an improving trend.

Does Acutaas Chemicals Ltd pay dividends?

Acutaas Chemicals Ltd has a dividend yield of 0.06 % at the current price of ₹2,332.00. The company pays dividends, though the yield is modest.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Acutaas Chemicals Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports